Osteoarthritis: The Rheumatologist's Perspective

Hochberg, Marc C.

doi:10.1007/s11420-011-9253-9

Cited by 11 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 It mainly affects people aged !45 years. 3 Knee OA has a high incidence and risk of mortality and affects more than 250 million people worldwide, 4 and it accounts for 1.0% to 2.5% of the gross domestic product. 5 Inflammation has been implicated in the pathogenesis of knee OA.…”

Section: Introductionmentioning

confidence: 99%

“…5 Inflammation has been implicated in the pathogenesis of knee OA. 3 Inflammatory pain is considered the most prominent feature in patients with moderate to severe knee OA. 6 However, some studies have revealed that a neuropathic mechanism that induces peripheral neuropathy with predominant sensory nerve fiber lesions 7,8 may lead to neuropathic pain during the last stage of knee OA.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial

Wang

2017

J Int Med Res

View full text Add to dashboard Cite

ObjectiveTo evaluate the efficacy and safety of adalimumab (ADA) versus hyaluronic acid (HA) by intra-articular injection for moderate to severe knee osteoarthritis.MethodsFifty-six consecutive patients with moderate to severe knee osteoarthritis were randomly allocated to either the ADA group or HA group. On day 0, patients in the ADA group received 10 mg of ADA by intra-articular injection, while those in the HA group received 25 mg of HA. All patients received celecoxib at 200 mg/day for 4 weeks. The pain visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Patient Global Assessment (PGA), and Physician Global Assessment (PhGA) scores were assessed.ResultsAt baseline, the pain VAS, WOMAC, PGA, and PhGA scores were similar between the two groups. The decrease in the pain VAS score, WOMAC pain score, WOMAC physical function score, and WOMAC total score from baseline to week 4 were greater in the ADA than HA group. A greater decrease in the PGA and PhGA scores from baseline to week 4 was noted in the ADA than HA group. No difference in adverse events was observed between the two groups.ConclusionADA by intra-articular injection was effective and tolerated for moderate to severe knee osteoarthritis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial

Wang

2017

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…It was demonstrated that CS reduced the nuclear translocation of NF‐kB in vitro [Du Souich et al, ; Calamia et al, ]. Recently, Calamia et al [] have reported the effective use of CS coupled to glucosamine in the treatment of osteoarthritis (OA) for its anti‐inflammatory properties [Hochberg, ]. In osteoarthritis, CS may stimulate the synthesis of proteoglycans and decrease the catabolic activity of chondrocytes through inhibition of proteolytic enzymes and other factors that contribute to tissue degradation.…”

mentioning

confidence: 99%

Biotechnological Chondroitin a Novel Glycosamminoglycan With Remarkable Biological Function on Human Primary Chondrocytes

Stellavato¹,

Tirino²,

Novellis³

et al. 2016

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cartilage tissue engineering, with in vitro expansion of autologus chondrocytes, is a promising technique for tissue regeneration and is a new potential strategy to prevent and/or treat cartilage damage (e.g., osteoarthritis). The aim of this study was (i) to investigate and compare the effects of new biotechnological chondroitin (BC) and a commercial extractive chondroitin sulfate (CS) on human chondrocytes in vitro culture; (ii) to evaluate the anti‐inflammatory effects of the innovative BC compared to extractive CS. A chondrogenic cell population was isolated from human nasoseptal cartilage and in vitro cultures were studied through time‐lapse video microscopy (TLVM), immunohistochemical staining and cytometry. In order to investigate the effect of BC and CS on phenotype maintainance, chondrogenic gene expression of aggrecan (AGN), of the transcriptor factor SOX9, of the types I and II collagen (COL1A1 and COL1A2), were quantified through transcriptional and protein evaluation at increasing cultivation time and passages. In addition to resemble the osteoarthritis‐like in vitro model, chondrocytes were treated with IL‐1β and the anti‐inflammatory activity of BC and CS was assessed using cytokines quantification by multiplex array. BC significantly enhances cell proliferation also preserving chondrocyte phenotype increasing type II collagen expression up to 10 days of treatment and reduces inflammatory response in IL‐1β treated chondrocytes respect to CS treated cells. Our results, taken together, suggest that this new BC is of foremost importance in translational medicine because it can be applied in novel scaffolds and pharmaceutical preparations aiming at cartilage pathology treatments such as the osteoarthritis. J. Cell. Biochem. 117: 2158–2169, 2016. © 2016 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc.

show abstract

“…It is certainly a significant cause of morbidity, and it has been recently recognized as a source of increased mortality. 1 In this regard, a recent systematic review reported that patients with symptomatic hip or knee OA had 55% greater all-cause mortality compared with the general population. Furthermore, a history of walking disability or limitation has been shown to be coupled with all-cause mortality and mortality due to cardiovascular disease, even after adjustment for age and sex.…”

Section: See Related Article On Page 106mentioning

confidence: 99%

Editorial Commentary: Platelet-Rich Plasma for Knee Osteoarthritis: A “Novel” and Effective Symptomatic Approach

Chahla

Cole

2019

Arthroscopy: The Journal of Arthroscopic & Related Surgery

View full text Add to dashboard Cite

Osteoarthritis (OA) constitutes a significant cause of disability, and it is now recognized as a source of increased mortality. Thus, several therapeutic approaches have been reported in the literature in an attempt to mitigate the symptoms of OA with varying degrees of success. Platelet-rich plasma (PRP) is being increasingly accepted as one of the most efficacious approaches for the symptomatic treatment of mild to moderate OA. Several confounding factors can affect the outcome of PRP such as age, grade of OA, PRP processing technique, and number and timing of these injections. However, numerous reports in the literature derived from PRP randomized clinical trials (compared with saline, hyaluronic acid, and other nonsurgical methods) suggest that successful outcomes can be achieved at least at 1-year postinjection with minimal complications.

show abstract

Osteoarthritis: The Rheumatologist's Perspective

Cited by 11 publications

References 9 publications

Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial

Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial

Biotechnological Chondroitin a Novel Glycosamminoglycan With Remarkable Biological Function on Human Primary Chondrocytes

Editorial Commentary: Platelet-Rich Plasma for Knee Osteoarthritis: A “Novel” and Effective Symptomatic Approach

Contact Info

Product

Resources

About